Oncotarget

Reviews:

Recent Advances in Anti-Angiogenic Therapy of Cancer

Rajeev S. Samant and Lalita A. Shevde _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2011; 2:122-134. https://doi.org/10.18632/oncotarget.234

Metrics: PDF 2934 views  |   HTML 4976 views  |   ?  


Abstract

Rajeev S. Samant and Lalita A. Shevde

*Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

Keywords: angiogenesis, tumor progression, metastasis, VEGF, angiogenesis inhibitors

Received: February 28, 2011; Accepted: March 7, 2011; Published: March 7, 2011;

Correspondence:

Rajeev S. Samant, e-mail:

Lalita A. Shevde, e-mail:

Abstract

Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical trials all over the world. This review discusses agents that have approved by the FDA and are currently in use for treating patients either as single-agents or in combination with other chemotherapeutic agents.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 234